The Study of Evaluating the Epstein - Barr virus Molecular Polymorphism and Tumor Biomarkers Associated with Non-Hodgkin's Lymphoma in Iraqi Patients

Abstract

Introduction: This study aimed to assess Epstein Barr virus molecular polymorphism and tumor biomarkers associated with non-Hodgkin’s lymphoma in some Iraqi patients. Methodology: This study involved 50 cases in Hawler Medical University, Erbil (Hawler) in the Kurdistan Region of Iraq from January 2020 through March 2021. Results: The distribution of patients by sex showed an increase statistical of men 60% and 40% of women, most of the patients from the capital region (Baghdad) with a frequency of 30%, then Erbil with a frequency of 20% and  Diyala:15%, Wasit:15%, Thi Qar:10%, and Al-Najaf: 10%. The high-frequency distribution of anti-EBNA- l IgGAb was data 19 cases (47.5%) in the age group (60-74)years, followed by 8cases (20.2%), in the age group 45-59 and 5 cases (12.5%) recorded in age group ˃75 years and 30-44 years respectively while the lowest level 3(7.5%) show in the age group 15-29 years. EBNA- l IgGAb showed 23 cases (57.5%) in males was higher than anti-EBNA- l IgMAb in 16 cases (76.1) while in females IgG was 17 cases (42.5%) and for IgM 5 cases (23.8). The majority of patients (64%) present with ATCD, heart disease presents a large percentage either 30% followed by type 2 diabetes or 24% while hypertension and tuberculosis have only been presented. by 8% and 2% for each and only 36% of patients did not present with DCDA. and Molecular study recorded the Level of L1PA2 Gene Expression significant increase in lymphoma patients' level of L1PA2 gene expression in the blood tissue. and MicroRNA-532-5p gene recorded a significant decrease in the level of lymphoma patients of patients with non-Hodgkin's lymphoma compared with the control group.Conclusion: Follicular lymphoma is the second most common type of non-Hodgkin lymphoma 3 to 4% of all cancers diagnosed worldwide as well as they represent 5 to 10% of new cases of cancer, the fifth cancer, but also the fifth cause of death., since follicular lymphoma continues to be incurable with currently available chemotherapy. ki-67 and Top2a expression in disease progression in patients with follicular lymphoma, since higher rates of these markers are significantly related to shorter disease progression time after chemotherapy. Only Ki-67 was significantly related to the overall survival in these patients, with those with higher rates having less favorable survival.